X PARSOLEX PARTNER SOLUTIONS EXCELLENCE
LIVE

Serial Number

88570483

Owner

Parsolex GMP Center, Inc.

Attorney

Jill J. Chalmers

First Use Date

Oct 28, 2019

Filing Date

Aug 7, 2019

Add to watchlist:

No watchlists yet
View on USPTO

X PARSOLEX PARTNER SOLUTIONS EXCELLENCE Trademark

Serial Number: 88570483 • Registration: 6356727

X PARSOLEX PARTNER SOLUTIONS EXCELLENCE is a trademark filed by Parsolex GMP Center, Inc. on August 7, 2019. The trademark is classified under Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Parsolex GMP Center, Inc. (9 trademarks)

West Lafayette, IN 47906

Entity Type: 03

Trademark Details

Filing Date

August 7, 2019

Registration Date

May 18, 2021

First Use Anywhere

October 28, 2019

First Use in Commerce

October 28, 2019

Published for Opposition

July 28, 2020

Goods & Services

Consulting services in the fields of pharmaceutical, medical and healthcare research and development; technical services, namely, research and development in the pharmaceutical and biotechnology fields; consulting services for pharmaceutical formulation design, design of processes to transform inorganic and organic substances and pharmaceutical technology transfer being advice and information about pharmaceutical research and design; technical services, namely, providing advice, information and instructions for pharmaceutical formulation design and design of processes to transform inorganic and organic substances, pharmaceutical technology transfer being advice and information about pharmaceutical research and design; pharmaceutical product chemical and physical evaluation services, namely, test method development, test method validation, use of test methods for in-process control, quality control, and product release, and technology transfer being advice and information about pharmaceutical test methods; analytical chemistry services, namely, developing and validating test methods for drug product release; technology transfer being advice and information about the drug product testing process and test methods; providing services to others in the fields of analytical, chemistry and manufacturing controls for the production and regulatory approval of pharmaceuticals, namely, providing scientific information relating to the analysis and management of the pharmaceutical manufacturing process for the production, packaging, and regulatory approval of pharmaceuticals; consulting services in the fields of chemistry, biotechnology, pharmaceutical research and development, laboratory testing, and diagnostics; consulting and research and development services in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; technical consulting in the fields of pharmaceutical studies, research and development; technical consulting in the field of pharmaceutical development and engineering; technical consulting in the field of analytical chemistry services; consultancy pertaining to pharmacology; technology consultation in the fields of research and development of pharmaceuticals, medicines and healthcare products; scientific research consulting in the fields of pharmaceuticals, medicines and healthcare products; product development consulting in the fields of pharmaceuticals, medicines and healthcare products; scientific research services relating to pharmaceuticals, medicines and healthcare products; product development consultation; product development services; formulation and process design services for drug products for others; outsource service provider for manufacturing and packaging of pharmaceuticals; formulation and process design services for drug products for others; design of packaging for pharmaceuticals of others; pharmaceutical product packaging design services for others; formulation and process design services for drug products of others; provision of information, advice and consultancy in relation to pharmaceutical packaging design; technical consulting in the field of pharmaceutical research and development; custom pharmaceutical service provider, namely, pharmaceutical formulation design, design of processes to transform inorganic and organic substances, and chemical and physical evaluation of pharmaceuticals; consulting in the areas of pharmaceutical formulation design, design of processes to transform inorganic and organic substances, and chemical and physical evaluation of pharmaceuticals; development of custom pharmaceuticals for others; design of packaging for pharmaceuticals for others; formulation and process design services for drug products for others

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
May 18, 2026 REM1
REGISTERED-PRINCIPAL REGISTER
May 18, 2021 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Apr 16, 2021 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Apr 15, 2021 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Apr 2, 2021 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Apr 1, 2021 AITU
USE AMENDMENT FILED
Mar 17, 2021 IUAF
TEAS STATEMENT OF USE RECEIVED
Mar 17, 2021 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 22, 2020 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 28, 2020 NPUB
PUBLISHED FOR OPPOSITION
Jul 28, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 8, 2020 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jun 24, 2020 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 16, 2020 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 16, 2020 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 16, 2020 GNEN
EXAMINERS AMENDMENT E-MAILED
Jun 16, 2020 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 16, 2020 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Jun 16, 2020 ZZZX
WITHDRAWN FROM ISSUE - MANAGING ATTORNEY REQUEST
Jun 15, 2020 ISMR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 26, 2020 NPUB
PUBLISHED FOR OPPOSITION
May 26, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 6, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 22, 2020 CNSA
EXAMINER'S AMENDMENT ENTERED
Apr 22, 2020 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 22, 2020 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 22, 2020 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 22, 2020 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 16, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 16, 2020 CRFA
ASSIGNED TO LIE
Apr 15, 2020 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 8, 2020 TROA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Oct 31, 2019 GPRN
PRIORITY ACTION E-MAILED
Oct 31, 2019 GPRA
PRIORITY ACTION WRITTEN
Oct 31, 2019 CPRA
ASSIGNED TO EXAMINER
Oct 16, 2019 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Aug 27, 2019 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 24, 2019 NWOS
NEW APPLICATION ENTERED
Aug 10, 2019 NWAP